经皮免疫接种针对不可分型流感嗜血杆菌双黏附素免疫原可诱导持久且可加强的免疫
不可分型流感嗜血杆菌(NTHI)是儿童中耳炎主要病原。研究用嵌合免疫原chimV4联合佐剂dmLT经创可贴经皮免疫(TCI),在灰鼠模型中评估免疫持久性与可加强性。结果出现快速细菌清除和疾病消退加速,鼻相关淋巴组织中成熟B细胞和抗体分泌细胞增加,两个月后加强进一步升高,表明该免疫策略可诱导持久且可加强的免疫。
要点
- chimV4靶向NTHI的OMP P5和IV型菌毛两种黏附素。
- chimV4+dmLT经创可贴TCI在灰鼠模型诱导快速细菌清除和疾病消退加速。
- TCI增加鼻相关淋巴组织成熟B细胞和抗体分泌细胞,两个月后加强进一步增强。
核心结论
- 创可贴经皮免疫chimV4+dmLT可诱导持久且可加强的免疫,支持其作为NTHI所致中耳炎的高效附加免疫策略。
研究设计与样本
- 在灰鼠模型中评估chimV4+dmLT经创可贴经皮免疫后的免疫持久性与可加强性。
- 免疫后连续两次中耳NTHI攻击,观察细菌清除和疾病消退。
- 检测鼻相关淋巴组织中成熟B细胞表型和抗体分泌细胞,并在两个月后再次TCI观察加强反应。
主要发现
- chimV4+dmLT经创可贴免疫后连续两次中耳NTHI攻击,出现快速细菌清除和显著加速的疾病消退。
- TCI显著增加鼻相关淋巴组织中成熟B细胞表型和抗体分泌细胞。
- 两个月后再次TCI,上述鼻相关淋巴组织反应进一步增强。
临床怎么用
- 作者认为,chimV4+dmLT经皮免疫的简便性和非侵入性支持其作为NTHI所致中耳炎高效附加免疫策略的效用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Otitis media (OM) is a very common pediatric disease and nontypeable Haemophilus influenzae (NTHI) is the predominant causative agent. We've developed a chimeric immunogen, chimV4, that simultaneously targets two NTHI adhesins, OMP P5 and the type IV pilus. Transcutaneous immunization (TCI) via bandaid with chimV4 plus the adjuvant dmLT provides significant protection against experimental NTHI-induced OM in chinchilla models. Herein, we now examined the durability and boostability of the induced immune response. Bandaid immunization with chimV4+dmLT followed by two sequential middle ear challenges with NTHI resulted in rapid bacterial clearance and significantly accelerated disease resolution. Moreover, TCI with chimV4+dmLT significantly increased mature B-cell phenotypes and antibody-secreting cells within nasal-associated lymphoid tissues, a response that was further augmented upon TCI two months later. Thus, bandaid immunization induced durable and boostable immunity. The simplicity and non-invasive nature of TCI with chimV4+dmLT supports its utility as a highly effective additional immunization strategy for NTHI-induced OM.
引用
- Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020. PMID: 32001071. doi:10.1016/j.vaccine.2020.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。